Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.

Analgesics, Opioid / therapeutic use Australia Community Pharmacy Services / organization & administration Drug Monitoring Drug Overdose / prevention & control Harm Reduction Humans Opioid-Related Disorders Pharmacists / organization & administration Pilot Projects Population Surveillance / methods Prescription Drug Misuse / prevention & control
Community pharmacy Implementation study Naloxone Opioids Overdose Pharmacy practice

Journal

Research in social & administrative pharmacy : RSAP
ISSN: 1934-8150
Titre abrégé: Res Social Adm Pharm
Pays: United States
ID NLM: 101231974

Informations de publication

Date de publication:
08 2019
Historique:
received: 30 03 2018
revised: 10 08 2018
accepted: 17 10 2018
pubmed: 7 11 2018
medline: 24 3 2020
entrez: 7 11 2018
Statut: ppublish

Résumé

Increases in opioid use and related harms such as mortality are occurring in many high income countries. Community pharmacists are often in contact with patients at risk of opioid-related harm and represent an ideal point for intervention. Best practice in monitoring opioid-related outcomes involves assessing analgesia, pain functioning, mood, risks and harms associated with opioid use. Community pharmacists are well-placed to undertake these tasks. Our pilot study will test the implementation of a computer-facilitated screening and brief intervention (SBI). The SBI will support pharmacist identification of opioid-related problems and provide capacity for brief intervention including verbal reinforcement of tailored information sheets, supply of naloxone and referral back to the opioid prescriber. The SBI utilises software that embeds study procedures into dispensing workflow and assesses opioid outcomes with domains aligned with a widely accepted clinical framework. We will recruit and train 75 pharmacists from 25 pharmacies to deliver the Routine Opioid Outcome Monitoring (ROOM) SBI. Pharmacists will complete the SBI with up to 500 patients in total (20 per pharmacy). Data will be collected on pharmacists' knowledge and confidence through pre- and post-intervention online surveys. Data on feasibility, acceptability and implementation outcomes, including naloxone supply, will also be collected. Our study will examine changes in pharmacists' knowledge and confidence to deliver the SBI. Through the implementation pilot, we will establish the feasibility and acceptability of a pharmacist SBI that aims to improve monitoring and clinical management of patients who are prescribed opioids.

Sections du résumé

BACKGROUND
Increases in opioid use and related harms such as mortality are occurring in many high income countries. Community pharmacists are often in contact with patients at risk of opioid-related harm and represent an ideal point for intervention. Best practice in monitoring opioid-related outcomes involves assessing analgesia, pain functioning, mood, risks and harms associated with opioid use. Community pharmacists are well-placed to undertake these tasks.
OBJECTIVES
Our pilot study will test the implementation of a computer-facilitated screening and brief intervention (SBI). The SBI will support pharmacist identification of opioid-related problems and provide capacity for brief intervention including verbal reinforcement of tailored information sheets, supply of naloxone and referral back to the opioid prescriber. The SBI utilises software that embeds study procedures into dispensing workflow and assesses opioid outcomes with domains aligned with a widely accepted clinical framework.
METHODS
We will recruit and train 75 pharmacists from 25 pharmacies to deliver the Routine Opioid Outcome Monitoring (ROOM) SBI. Pharmacists will complete the SBI with up to 500 patients in total (20 per pharmacy). Data will be collected on pharmacists' knowledge and confidence through pre- and post-intervention online surveys. Data on feasibility, acceptability and implementation outcomes, including naloxone supply, will also be collected.
PROJECT IMPACT
Our study will examine changes in pharmacists' knowledge and confidence to deliver the SBI. Through the implementation pilot, we will establish the feasibility and acceptability of a pharmacist SBI that aims to improve monitoring and clinical management of patients who are prescribed opioids.

Identifiants

DOI: 10.1016/j.sapharm.2018.10.024 PMID: 30396825
pubmed: 30396825
pii: S1551-7411(18)30285-7
doi: 10.1016/j.sapharm.2018.10.024
pii:
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1047-1055

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Suzanne Nielsen (S)

National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia; Monash Addiction Research Centre, Monash University, Melbourne, Australia. Electronic address: suzanne.nielsen@monash.edu.

Michala Kowalski (M)

National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia.

Pene Wood (P)

Latrobe University, Bendigo, Victoria, Australia; Western Victoria Primary Health Network, Geelong, Victoria, Australia.

Sarah Larney (S)

National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia.

Raimondo Bruno (R)

National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia; School of Medicine, University of Tasmania, Hobart, Australia.

Marian Shanahan (M)

National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia.

Simon Lenton (S)

National Drug Research Institute, Curtin University, Perth, Australia.

Paul Dietze (P)

The Centre for Population Health, Burnet Institute, Melbourne, Victoria, Australia; The School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Traci Green (T)

Department of Epidemiology, Brown University School of Public Health, Rhode Island, USA; Boston Medical Center, Injury Prevention Center, Boston University School of Medicine, Boston, USA.

Bridin Murnion (B)

Department of Addiction Medicine, University of Sydney, Sydney, Australia.

Alison Ritter (A)

National Drug and Alcohol Centre, University of New South Wales, Sydney, Australia; Drug Policy Modelling Program, University of New South Wales, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Stupéfiants › Analgésiques morphiniques › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Australie › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Services pharmaceutiques › Services des pharmacies communautaires › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Monitorage physiologique › Surveillance des médicaments › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Mésusage de médicament › Surdose › Mauvais usage des médicaments prescrits › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Réduction des dommages › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Troubles liés à l'usage de substances psychotropes › Troubles liés aux opiacés › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Pharmaciens › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Projets pilotes › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Surveillance de la population › Routine opioid outcome monitoring in community...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Mésusage de médicament › Surdose › Routine opioid outcome monitoring in community...